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Acute coronary syndromeAbstract Aim and background: Heart-type fatty acid-binding proteins (H-FABP) which are
detected within 2–3 h of acute myocardial infarction are involved in uptake of free fatty acids in
the myocardium. Our aim in the present study is to compare window periods of H-FABP to high
sensitivity troponin T (hs-Trop T) in acute ST elevation myocardial infarction (STEMI).
Methods: 160 STEMI diagnosed patient’s serum samples are analyzed for hs-Trop T and
H-FABP. Different window periods of chest pain onset (<3 h, 3–6 h and >6 h) are compared with
complications, in-hospital mortality and statistically analyzed.
Results: From 160 patients, 53 (33%) cases are presented in <3 h, 75 (47%) in 3–6, and 32
(20%) after >6 h respectively. Accordingly sensitivity of hs-Trop T was 92%, 94% and 97% while
H-FABP was 75%, 88% and 84%, respectively. Overall sensitivity was 94% and 82% respectively.
Statistically signiﬁcant difference between mean hs-Trop T values with respect to window period
<3, 3–6 and >6 h was 0.21, 0.35 and 0.80 ng/ml respectively, p value < 0.0001. No signiﬁcant
difference in H-FABP values was observed.
Hs-Trop T positively correlated with age (r= 0.153, P= 0.05), window period (r= 0.363,
P< 0.0001), TIMI score (r= 0.208, P= 0.008), ejection fraction (r= 0.191, P= 0.008), serum
H-FABP (r= 0.229, P= 0.004), and serum hs-CRP (r= 0.326, p< 0.001). There was a statisti-
cally signiﬁcant difference of mean hs-Trop T values with or without in hospital mortality (0.35
vs. 0.85 ng/ml, respectively, p= 0.008).
Comparative study of hs-Trop T and H-FABP 57No signiﬁcant correlation to age, TIMI score, ejection fraction and hs-CRP values for H-FABP
was observed.
Conclusion: It appears that hs-Trop T is a more sensitive marker than H-FABP in early hours of
AMI and higher hs-Trop T predicts increase in-hospital mortality.
ª 2014 Production and hosting by Elsevier B.V. on behalf of King Saud University.1. Introduction
Heart-type fatty acid-binding protein (H-FABP) is a low-
molecular-weight protein involved in the intracellular uptake
and buffering of free fatty acids in the myocardium (Glatz
et al., 1997). It was ﬁrst noted to be a marker of myocardial
infarction (MI) in 1988 Glatz et al., 1988. Heart-type fatty
acid-binding protein is smaller in size (14–15 kDa) than tropo-
nin I or T (21–37 kDa) and is concentrated in the cytoplasm of
cardiomyocytes. Owing to its small size, H-FABP is released
quickly into the circulation when membrane integrity is com-
promised in response to myocardial injury. Levels of H-FABP
are detectable as early as 2–3 h and typically return to baseline
levels within 12–24 h of the initial insult (Tanaka et al., 1991;
Kleine et al., 1992). Moreover, because of its rapid release
kinetics, H-FABP might be useful for the detection of reperfu-
sion after ST-segment elevation MI (de Lemos et al., 2000).
These properties make H-FABP theoretically, an attractive
marker both for the detection of myocardial ischemia in the
absence of necrosis and possibly for the early detection of
recurrent myocardial injury.
Based on this background we wanted to assess the role of
H-AFBP in early hours of acute myocardial infarction, and
compare its window period response with that of high sensitive
troponin T (hs-TnT).
2. Methods
We selected 160 consecutive patients with diagnosis of acute
ST elevation myocardial infarction (STEMI) admitted to the
coronary care unit (CCU) at Sri Jayadeva Institute of Cardiol-
ogy and Research, Bangalore. Following Helsinki declaration
and Institute regulatory board guidelines, patient consent was
obtained and a cross sectional study, conducted from Decem-
ber 2012 to April 2013.
Inclusion criterion was, patients diagnosed as STEMI
based on European Society of Cardiology ESC/American Col-
lege of Cardiology Foundation ACCF/American Heart Asso-
ciation AHA/World Heart Foundation WHF Third Universal
Deﬁnition of MI Thygesen et al. (2012) while exclusion criteria
were that, patients with diagnosis of unstable angina, No ST
elevation myocardial infarction (NSTEMI), and STEMI
patients who underwent primary Percutaneous Coronary
Intervention (PCI).
2.1. Method
At study entry, a relevant history was taken and focused phys-
ical examination was done, the data acquired included age,
gender, body mass index (BMI), blood pressure, and assess-
ment of risk factors including a history of MI/old coronary
vascular atherosclerosis CVA. During baseline evaluation,
symptoms were assessed, vitals recorded, Killip class wasassessed, and TIMI score was calculated for all patients.
Patient’s blood samples were drawn at admission to the Criti-
cal Care Unit (CCU) for analysis of random blood glucose,
renal function test, serum electrolytes, lipid parameters, com-
plete blood count, hs-TnT and HAFBP. An echocardiographic
evaluation of the left ventricular ejection fraction (LVEF) was
performed in all participants within 24 h of hospital admission.
2.2. Laboratory analyses
Hs-Trop T was measured with the Elecsys Troponin T immu-
noassay (Roche Diagnostics, Germany), the cut off value used
was 0.014 6 ng/ml which represented the lowest concentration
at which the coefﬁcient of variance (CV) was 10%. An
increased hs-Trop T concentration is deﬁned as a value exceed-
ing the 99th percentile of a normal reference population [upper
reference limit (URL)] Thygesen et al., 2012.
The H-FABP was measured with the Biochip array technol-
ogy (Randox Laboratories, Ltd., Co.,Antrim, United King-
dom). As per the manufacturer’s claim this biochip uses a
high precision assay for measuring H-FABP with 2 mouse
monoclonal antibodies with a sensitivity of <2.5 ng/ml and
linearity up to 120.0 ng/ml. The 99th percentile cut-off value
is 66.32 ng/ml with the inter-assay CV to be <5% at a con-
centration of 6.32 ng/ml (99th percentile values). An increased
H-FABP concentration is deﬁned as a value exceeding the 99th
percentile of a normal reference population [upper reference
limit (URL)].
2.3. Statistical analysis
The statistical analyses were performed with Statistical Pack-
age for the Social Sciences (SPSS), version 16.0. (SPSS Inc.,
Chicago, Illinois). Baseline characteristics were assessed with
Student’s t-test (parametric) and Mann–Whitney U test (non-
parametric) for continuous variables, and the Chi-square test
(v2 test) for categorical variables, with two-tailed P-values,
<0.05 taken as signiﬁcant. The Mann–Whitney U test was
used to compare biomarker levels between two independent
groups.
3. Results
3.1. Baseline characteristics
Out of total 160 patients analyzed, 142 (88%) were males, 18
(11%) were females, mean age was 54 .31 ± 11. Window per-
iod (WP) varied from 0.5 h to 24 h, with a mean WP of
5.15 ± hours. Coronary risk factor frequencies were: high
blood pressure in 37% and diabetes in 39%, past history of
Ischemic heart disease IHD or CVA present in 11%, current
smoking habit present in 54%; family history of IHD present
in 2.5% of patients, and dyslipidemia present in 83% of
Table 1 Patient distribution of window period.
Window period n %
<3 h 53 33
3–6 h 75 47
>6 h 32 20
Total 160 10
58 S. Banu et al.patients. Elective PCI revealed anterior wall myocardial infarc-
tion (AWMI) as most common type of MI occurring in 81
patients (51%). Lateral wall MI (LWMI) was least common
type occurring in only 1.2% of patients.
Table 1 shows number of patients based on window period.
53 (33%) patients presented within 3 h, 75 (47%) patients pre-
sented between 3 and 6 h, and 32 (20%) patients presented
after 6 h. Out of 160 patients, 9 (5.4%) patients had hs-Trop
T value 60.01 ng/ml, 26 (16.2%) patients had H-FABP value
66.32 ng/ml (p value <0.001), in 134 (83.8%) patients both
biomarkers were elevated (positive) while in 6 (3.8%) patients
both were less than 99th percentile values (negative).
The relation of H-FABP and hs-Trop T with regard to dif-
ferent window periods showed that 53 (33%) patients presented
within 3 h of chest pain, among these 4 (7.5%) patients had
normal hs-Trop T values whereas 13 (24.5%) patients had nor-
mal H-FABP values (p value = 0.015). In this group only 3
(5.7%) patients had normal values for both the biomarkers.
Among patients who presented between 3 and 6 h, 4 (5.3%)
patients had normal hs-Trop T, whereas 9 (12%) patients had
normal H-FABP (P< 0.0001). In patients with history of more
than 6 h of chest pain there was no signiﬁcant difference
between hs-Trop T and H-FABP values (p> 0.05). In this
study it has been seen that combined H-FABP and hs-Trop T
values were elevated in 49 (30%) patients in 63 h group while
only 3 patients had both biomarkers normal. Similarly it is
observed that 71 out of 75 patients who presented between 3
and 6 h had both biomarkers elevated only 3 patients had nor-
mal values. Among those presenting more than 6 h 27 (16%)
had both bio markers elevated.
Statistically signiﬁcant difference between mean hs-Trop T
values with respect to window period <3 h, 3–6 h, and >6 h
was 0.21, 0.35 and 0.80 ng/ml, respectively, p value < 0.0001.
Similarly when we analyzed H-FABP (Table 2) with respectTable 2 H-FABP mean values with respect to window period.
Window period n Mean Std. deviation SE of mean
<3 h 53 71.97 173.60 23.85
3–6 h 75 76.36 78.03 9.01
>6 h 32 119.95 140.17 24.78
Table 3 showing sensitivity of hs-Trop T and H-FABP.
WP 6 3 h (%) WP> 3–6 h (%)
Hs-Trop T 92 94
H-FABP 75 88
Combined 84 91to window periods <3 h, 3–6 h, and >6 h, though the mean
values increased in these groups respectively, however there
was no statistical signiﬁcant difference among these groups
(71.97, 76.36 and 119.95 ng/ml, respectively, p= 0.206).
Sensitivity of hs-Trop T and H-FABP with respect to win-
dow period is that hs-Trop T was 92% sensitive and whereas
H-FABP was 75% sensitive in patients presenting with <3 h
of onset of symptoms, this appears different, than that claimed
by the manufacturer. The sensitivity of hs-Trop T and H-
FABP in patients presenting between 3 and 6 h was 94%
and 88%, respectively. Similarly the sensitivity of hs-Trop T
and H-FABP in patients presenting after 6 h was 97% and
84%, respectively. Overall sensitivity for hs-Trop T and H-
FABP in this study was 94% and 82%, respectively (Table 3).
Relation of hs-Trop T and H-FABP to various biochemical
and clinical co-relations is that, hs-Trop T positively correlates
with age (r= 0.153, P= 0.05), window period (r= 0.363,
P< 0.0001), TIMI score (r= 0.208, P= 0.008), ejection frac-
tion (r= 0.191, P= 0.008), serum HAFBP (r= 0.229,
P= 0.004), and serum hs-CRP (r= 0.326, p< 0.001) .
Similar analysis with H-FABP showed a positive correla-
tion with window period, hs-Trop T (r= 0.229, P= 0.004),
and hs-CRP (r= 0.986, p< 0.001). There was no correlation
between H-FABP and important parameters like age, TIMI
score, and ejection fraction.
When we analyzed hs-Trop T and H-FABP with respect to
the presence or absence of hospital complications, there was
no statistically signiﬁcant difference between these two
biomarkers.
Out of 160 STEMI patients, 9% (15) patients died during
their in hospital stay. In hospital mortality and mean values
of hs-Trop T, HFABP, and hs-CRP showed no statistically
signiﬁcant difference for H-FABP and hs-CRP values between
patients with or without mortality (p= 0.18, and p= 0.81
respectively Table 4). There was a statistically signiﬁcant dif-
ference of mean hs-Trop T values with or without in-hospital
mortality (0.35 vs. 0.85 ng/ml, respectively, p= 0.008).
4. Discussion
Cardiac troponin remains the cornerstone in the diagnosis and
risk stratiﬁcation of patients with suspected ACS. One of the
important criteria for a biomarker is to help early clinical95% CI for mean Min Max. P-Value
Lower bound Upper bound
24.12 119.82 0.22 1178.45 0.206
58.41 94.32 0.77 457.65
69.41 170.49 2.77 647.00
WP> 6 h (%) Overall sensitivity (%)
97 94
84 82
92 89
Table 4 Hs-Trop T, H-FABP, hs-CRP and in hospital mortality.
In hospital mortality N Mean Std. deviation Std. error mean P-Value
H-FABP Absent 145 73.5712 95.17411 7.90378 0.184
Present 15 109.5502 108.49279 28.99592
Hs-CRP Absent 145 0.7028 0.86859 0.07213 0.816
Present 15 0.6479 0.39184 0.10472
Hs-trop T Absent 145 0.3557 0.62770 0.05231 0.008*
Present 15 0.8502 0.89294 0.23865
*
indicates value of Hs Troponin T is most signiﬁcant that other biomarkers.
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(Morrow and de Lemos, 2007). Growing number of studies
have shown that H-FABP is a sensitive marker for the diagno-
sis of myocardial infarction (MI) Tanaka et al., 1991; Glatz
et al., 1998; Okamoto et al., 2000; Seino et al., 2003. The char-
acteristic release of H-FABP after acute MI is that a rise is
detectable as early as 1.5 h after symptom onset, reaches a peak
level after 4–6 h and the level returns to baseline within 20 h due
to rapid renal clearance (Alhadi and Fox, 2004) H-FABP is
present at high concentrations within cardiac myocytes, and
at lower concentrations in other tissues such as skeletal muscle,
kidney, speciﬁc parts of the brain, lactating mammary glands,
and placenta (Pelsers et al., 2005). Early assays used antibodies
which had high degrees of cross-reactivity with other FABP
types. This may have hampered their clinical utility. More mod-
ern assays rely on monoclonal antibodies that have shown no
or minimal cross-reactivity (Roos et al., 1995).
Whereas troponin’s relative large size and location bound
within the contractile apparatus of the cardiomyocyte, make
its release typically delayed for several hours after the onset
of ischemic injury. Thus, blood must be sampled at least 6 h
after the onset of ischemic discomfort in order to achieve ade-
quate sensitivity. As such, for a large number of patients with-
out classic symptomatology or electrocardiographic changes,
signiﬁcant irreversible myocardial injury might occur before
a deﬁnitive therapeutic plan is implemented. In addition, tro-
ponin levels might remain elevated for 7–14 days after the ini-
tial ischemic insult, thereby limiting sensitivity for detecting
recurrent myocardial injury (de Lemos, 2007).
Our study was a cross sectional study, we compared hs-
Trop T and H-FABP in patients presenting with STEMI with
regard to window period. Also we analyzed these two bio-
markers with respect to various in hospital complications
and in hospital mortality. This study demonstrated that hs-
Trop T is more sensitive than H-FABP in patients who pre-
sented to hospital within 6 h. This present study showed that
measurement of H-FABP in patients with AMI at the time
of admission is useful and complements the measurement of
hs-Trop T although Hs-Trop T is a better marker than
HFABP. Our study demonstrated no signiﬁcant difference in
levels of both of these markers in the presence or absence of
in hospital complications.
In our study we evaluated sensitivity of hs-Trop T and H-
FABP with respect to window period. It is seen that hs-Trop
T was 92% sensitive and whereas H-FABP was 75% sensitive
in patients presenting with <3 h of onset of symptoms. This
observation further explains that HFABP did not perform
superior to hs-Trop T at <3 h of history of chest pain
although it complements the performance. The sensitivity of
hs-Trop T and H-FABP in patients presenting between 3and 6 h was 94% and 88%, respectively, the detection range
being somewhat similar in this period. Similarly the sensitivity
of hs-Trop T and H-FABP in patients presenting after 6 h was
97% and 84%, respectively. Overall sensitivity for hs-Trop T
and H-FABP in this study was 94% and 82%, respectively.
Studies evaluating the diagnostic accuracy of H-FABP have
reported variable sensitivities and speciﬁcities (Ishii et al.,
1997; Okamoto et al., 2000; Tanaka et al., 2006; Seino et al.,
2003; Glatz et al., 1998; Mad et al., 2007; Valle et al., 2008).
More recently, Mad et al. evaluated H-FABP levels in 280
patients presenting within 24 h of chest pain. H-FABP had a
sensitivity of 69% and speciﬁcity of 74% (Mad et al., 2007).
Valle et al. evaluated 419 patients presenting within 3 h of
chest pain, H-FABP had a sensitivity of 60% and speciﬁcity
of 88% (Valle et al., 2008). Seino et al. evaluated 371 patients
with chest pain and suspected MI. H-FABP had a sensitivity of
over 90% and a speciﬁcity of 50%. Thus all these studies show
a widely variable sensitivity and speciﬁcity of H-FABP (Seino
et al., 2003).
In a study McCann et al. demonstrated that, sensitivity of
cTnT for acute MI was 75% (95% CI 69–81). The sensitivity
of initial cTnT was at its lowest for patients who presented
within 4 h of symptom onset [55% (95% CI 44–66)]. It
increased with increasing time from symptom onset to admis-
sion, with a sensitivity of 97% (95% CI 83–99) for patients
who presented >12 h, the sensitivity of HFABP 73% in, 4 h,
78% >4 h (McCann et al., 2008). In a study done by Koenig
et al. (ROMICAT Study) in 377 ACS patients sensitivity, spec-
iﬁcity, positive predictive value and negative predictive value
of hs-Trop T were 62.2%, 88.9%, 37.7% and 95.6%, respec-
tively. Therefore the variation in performance of HFABP
may be due to several other factors and needs larger studies
to conﬁrm its utility as an early marker.
In our study hs-Trop T positively correlates with age
(r= 0.153, P= 0.05), window period (r= 0.363, P<
0.0001), TIMI score (r= 0.208, P= 0.008), ejection fraction
(r= 0.191, P= 0.008), serum HAFBP (r= 0.229, P=
0.004), and serum hs-CRP (r= 0.326, p< 0.001).
Similar analysis with H-FABP shows a positive correlation
with window period, hs-Trop T (r= 0.229, P= 0.004), and
hs-CRP (r= 0.986, p< 0.001). There was no correlation
between H-FABP and important parameters like age, TIMI
score, and ejection fraction.
There was no statistically signiﬁcant difference of H-FABP
and hs-CRP values between patients with or without mortality
(p= 0.18, and p= 0.81 respectively). There was a statistically
signiﬁcant difference of mean hs-Trop T values with or with-
out in-hospital mortality (0.35 vs. 0.85 ng/ml, respectively,
p= 0.008), suggesting that higher hs-Trop T level is associated
with increased in hospital mortality.
60 S. Banu et al.The ﬁndings of this study are similar to study done by Mat-
sui et al. the diagnostic and prognostic value of serum level of
hs-Trop T relative to H-FABP in the early hours of acute cor-
onary syndrome (ACS) in 460 consecutive patients hospital-
ized to the cardiac emergency department for suspected ACS
within 6 h after the onset of chest symptom. It showed that
increased hs-TnT (relative risk 14.5, P= 0.009), but not H-
FABP, was independently associated with cardiac events.
Patients with increased hs-TnT had a higher risk of cardiac
events within 12 months compared with those without
(14.1% vs. 0.5%, P< 0.0001). In that study the sensitivity
and speciﬁcity of hs-Trop T and H-FABP were 88% and
76% <3 h of presentation respectively and 91% and 76% in
patients presenting within 3 to 6 h. Overall sensitivity for hs-
Trop T and H-FABP was 90% and 76% respectively
(Matsui and Ishii, 2011). Antman et al. studied 597 patients
with acute coronary syndrome (ACS), and showed that the
composite end point of the sum of death, nonfatal myocardial
infarction or recurrent ischemia through day 14 occurred in
33.6% of patients with a positive assay for hs-Trop T com-
pared with only 22.5% of patients with a negative assay
(p< 0.01) Antman et al., 1998. This ﬁnding supports our
study that in hospital mortality was higher in patients with
higher hs-Trop T values.
The ﬁndings of our study are also supported by a study
done by Schoos et al. who studied 601 consecutive unselected
chest pain patients with 59 (9.8%) acute myocardial infarc-
tions (MI) and showed that in a single sample strategy, admis-
sion hs c TnTs are equipotent and superior to copeptin and H-
FABP. Hs-TnT has slightly better ‘ruling out’ and hs-TnI bet-
ter ‘ruling in’ capacities in diagnosing MI. In this study numer-
ically best diagnostic strategy was regardless of symptom
onset, the combination of hscTnI and H-FABP (Mikkel,
2013).
Dekker et al. in a study of 486 ACS suspected patients pre-
senting to the emergency department within 24 h of symptom
onset, showed that H-FABP testing improves diagnostic accu-
racy in addition to clinical ﬁndings and ECG. H-FABP how-
ever, has limited clinical diagnostic value in addition to cTnI
measurements in daily practice (Dekker et al., 2011).
There are various studies which support the role of H-
FABP in both diagnosis and prognosis of patients with acute
coronary syndrome. In a study done by McCann et al. in
patients with ACS showed that sensitivity of H-FABP for
acute MI was superior to cTnT for patients admitted within
4 h of symptom onset. For patients who were admitted 4 h
or more following symptom onset there was no signiﬁcant dif-
ference between the sensitivity of H-FABP and cTnT. The
results of this trial supported the use of H-FABP, measured
in combination with cTnT at the time of admission, to improve
upon early detection of acute MI. This combined approach
(either marker elevated) signiﬁcantly improved sensitivity for
acute MI of patients admitted within 12 h of symptom onset
(McCann et al., 2008).
In another study Kilcullen et al. evaluated the prognostic
utility of H-FABP in a registry of 1448 patients with ACS from
West Yorkshire, United Kingdom. Heart type fatty acid-bind-
ing protein was powerfully and independently associated with
the risk of death when measured within 12–24 h of symptom
onset after ACS. Moreover, H-FABP identiﬁed subjects at
increased risk of death even when troponin levels were normal
(Kilcullen et al., 2007).In a study Kilcullen et al. showed that the occurrence of a
negative test result for both TnI and H-FABP was associated
with zero mortality (no deaths) before 6 months. This appears
to represent a particularly worthwhile clinical outcome, espe-
cially because it was observed in patients admitted into hospi-
tal for suspected ACS. Such an observation would give
conﬁdence to physicians assessing unselected suspected ACS
patients in the emergency room, particularly if reproduced
using much earlier blood samples (Kilcullen et al., 2007).
In a study done by Viswanathan et al. in 1080 patients
consecutively admitted to the hospital with suspected ACS
the H-FABP concentration was an independent predictor of
death or myocardial infarction, after multivariate adjustment.
Patients with H-FABP concentrations >6.48 lg/l had signiﬁ-
cantly increased risk of adverse events (adjusted hazard ratio:
2.62, 95% conﬁdence interval: 1.30–5.28, p< 0.007). Among
troponin-negative patients (which constituted 79.2% of the
cohort), the aforementioned cutoff of 6.48 lg/l identiﬁed
patients at very high risk of adverse outcomes (Viswanathan
et al., 2010).
4.1. Study limitations
Limitations of the present study include the fact that we stud-
ied a high-risk cohort of patients with conﬁrmed ACS
(STEMI) and the results presented may not necessarily be
applicable to lower risk populations, such as all patients with
chest pain presenting to the emergency department. Second
limitation was the single blood sample taken for the study.
Sequential measurements were not investigated. Third limita-
tion of the study was small sample size. This is still an early
evaluation of H-FABP in terms of diagnostic utility more stud-
ies, clinical, and scientiﬁc questions remain to be answered,
and further large scale studies are required to assess the diag-
nostic ability of H-FABP.
5. Conclusion
Our study was intended to conﬁrm the theoretical report that
HFABP is a better marker to be used in the emergency setting
for patients with history of chest pain, but our research sug-
gests that hs-Trop T appears to have better sensitivity as a bio-
marker than H-FABP in early hours of STEMI acute
myocardial infarction. Compared to HFABP an abnormal
increase or levels of hs-Trop T is a better predictor of increased
in-hospital mortality. Therefore measurement of H-FABP in
patients with acute myocardial infarction at the time of admis-
sion is useful and complements the measurement of hs-Trop T.
Since a better conﬁrmation of the diagnosis can be made with
HFABP and hs-Trop T, using these markers together maybe
beneﬁcial.
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